AstraZeneca will acquire EsoBiotec for a total consideration of up to $1billion, on a cash and debt free basis. This will ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

Recruitment of Second Patient for HG-CT-1 Clinical Trial LONDON, GB / ACCESS Newswire / March 17, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce the recruitment of the second p ...

The tumult of large-scale cuts to federal spending, pullbacks of civil rights protections, and new tariffs getting announced ...

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test ...

Morgan said that every major health insurance provider currently is using AI in some way, both helpful and harmful to ...

CALR mutations occur in about 20% of patients with primary and post-essential thrombocythemia myelofibrosis, as per the study ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

On St Patrick's Day, investors hope for the luck of the Irish ahead of Opthea's key trial update and Imricor's ambitious fund ...